DD01 is a glucagon-like peptide-1 receptor / glucagon receptor (GLP-1R/GCGR) dual agonist for the treatment of obesity, nonalcoholic steatohepatitis and diabetes.
D and D will retain all rights for the rest of the world.
In connection with this agreement, D and D will receive an upfront payment of USD4 m and is eligible to receive additional undisclosed milestone payments upon achievement of certain development and commercial milestones, as well as double-digit royalties on future net sales.
DD01 is currently being investigated in a phase 1 clinical trial which is being conducted in the US
DD01 is a long-acting dual agonist of the GLP-1R receptor and glucagon receptor. In preclinical models of diabetes and nonalcoholic fatty liver disease (NAFLD), DD01 was capable of inducing reduction in weight and blood sugar and improvements in insulin sensitivity and lipid and fat metabolism that could ameliorate NASH.
DD01 demonstrated greater efficacy in preclinical models compared to semaglutide, an approved GLP-1R receptor agonist; from a mechanism perspective, the effect of DD01 persisted after cessation of treatment.
DD01 is a proprietary dual agonist of GLP-1R and glucagon receptors being developed as a potential disease-modifying agent for obese and liver fatty disease.
Treatment with DD01 caused weight loss, reduced liver fat and improved glucose tolerance in mouse models of obesity, diabetes and fatty liver disease.
D and D Pharmatech is a clinical-stage global biotech company that funds the development of revolutionary medicines through disease-specific subsidiary companies founded and guided by top-tier medical research faculty.
This corporate structure creates a unique opportunity to accelerate translation of cutting-edge research into lifesaving therapeutic products for patients.
The company's product pipeline focuses on a range of indications including neurodegenerative, fibrotic, and metabolic diseases. D and D Pharmatech is the parent company of US-based Neuraly Inc., Theraly Fibrosis Inc., Precision Molecular Inc. and Valted Seq Inc., and P4 Microbiome Inc.
Shenzhen Salubris Pharmaceuticals is a commercialization stage biopharmaceutical company with experience and expertise drug development and commercialization in the People's Republic of China.
The company covers chemical drugs, biological drugs and medical devices, providing a package of solutions for patients.
The company's product pipeline focuses on a range of indications including cardiovascular, renal, orthopedic, and metabolic diseases.
vTv Therapeutics secures USD51m private placement for cadisegliatin Phase 3 study
AbbVie names new chief executive officer
SkinBioTherapeutics expands foot care products in AMEA with Dermatonics partnership
Diamyd Medical granted US FDA Fast Track designation for Diamyd diabetes treatment
Insulet's Omnipod 5 integration with Abbott FreeStyle Libre 2 Plus Sensor secures CE Mark approval
Kyowa Kirin enrols first subject in phase two tivozanib eye drops (KHK4951) clinical trial
China accepts GSK's Shingrix application for at-risk adults
Novo Nordisk to boost manufacturing capacity with acquisition of three fill-finish sites
Breye Therapeutics commences phase 1b/2a danegaptide clinical trial
DexCom Inc breaks ground on new manufacturing facility in Ireland
VibroSense Dynamics AB secures provisional patent for chemotherapy-induced nerve damage prediction
Innovent Biologics signs collaboration agreement with Sanegene Bio USA
Japan approves GSK's filing for Arexvy vaccination for at-risk adults